PenKid biomarker provides decision support for kidney replacement therapy in critically ill patients, addressing an unmet clinical need
Executive summary: In a prospective real-world study of 1,436 critically ill ICU patients, penKid (proenkephalin A 119–159) provided clinically relevant information across AKI severity and during kidney replacement therapy. Addresses a key unmet need in kidney replacement therapy management by offering objective data to support therapy decisions.
Who is involved: Researchers studying ICU patients; the biomarker penKid; critically ill patients undergoing kidney replacement therapy.
Likely next: Further validation studies are needed to support broader adoption of penKid in clinical practice.
A prospective real-world study of 1,436 ICU patients showed that the biomarker proenkephalin A 119–159 (penKid) delivers clinically relevant information across AKI severity and during kidney replacement therapy. The data suggest that penKid can help guide therapy decisions where current tools are limited. This addresses a key unmet need in managing critically ill patients requiring renal support.
Timeline
- — New Real-World Data Show penKid Adding Decision Support for Kidney Replacement Therapy in Critical Care (PR Newswire)
Analysis — what this means
Sectors affected
- critical care nephrology
- hospital acute kidney injury management